Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Single-arm Phase II Study of LP002 in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

NCT04600947 is registered in ClinicalTrials.gov with Taizhou HoudeAoke Biomedical Co., Ltd. as lead sponsor.

NCT NCT04600947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04600947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Single-arm Phase II Study of LP002 in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Lead sponsor
Taizhou HoudeAoke Biomedical Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
December 30, 2020
Completion date
May 30, 2023
Enrollment
69 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

primary mediastinal large b-cell lymphoma (pmbcl)